Inicio・Lista de Acciones・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Abierto

SectorSanidad

47.02 -3.81

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

47.45

Máximo

49.23

Métricas clave
By Trading Economics
Ingresos	-56M -58M
Ventas	11M 219M
BPA	0.39
Margen de beneficios	-26.646
Empleados	778
EBITDA	-50M -30M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+34.32% upside

Dividendos
By Acuity
Próximas Ganancias	3 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	79M 2.8B
Apertura anterior	50.83
Cierre anterior	47.02

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

312 / 340 Clasificación en Healthcare

Supernus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 ago 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17 ago 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14 ago 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 ago 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 ago 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 ago 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 ago 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 ago 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 ago 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 ago 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 ago 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 ago 2026, 19:51 UTC

Social Media

News

Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 jul 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 jul 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

29 jul 2026, 17:26 UTC

Supernus Pharmaceuticals Inc. shares are lower today amid volatility, with no specific news identified. The stock remains below its 20-day moving average.

28 jul 2026, 17:06 UTC

Supernus Pharmaceuticals Inc. shares are higher today, recovering from an earlier decline. The stock remains near the lower end of its one-month trading range.

27 jul 2026, 20:06 UTC

Supernus Pharmaceuticals Inc shares are higher Monday, despite earlier gains pulling back. Market dynamics reflect a significant decline in oil prices and inflation reassessment.

24 jul 2026, 19:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, following an early peak, amid broader market dynamics influenced by a pullback in crude oil prices.

20 jul 2026, 20:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early high amid a broader market decline during the session.

Comparación entre iguales

Cambio de precio

Supernus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

34.32% repunte

Estimación a 12 Meses

Media 65.2 USD 34.32%

Máximo 67 USD

Mínimo 63 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

312 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.